Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765383 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HTTKDM4ENPC1KMT2A | |
| SCHEMBL13262062 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HTTKDM4ENPC1KMT2A | |
| SCHEMBL25376374 | 0.82 | HTT (0.48) | ALDH1A1HTTKDM4ENPC1KMT2A | |
| SCHEMBL19286209 | 0.80 | HTT (0.47) | ALDH1A1HTTKDM4ENPC1KMT2A | |
| SCHEMBL28276325 | 0.80 | HTT (0.47) | ALDH1A1HTTKDM4ENPC1KMT2A | |
| SCHEMBL2669165 | 0.79 | ALDH1A1 (0.54) | ALDH1A1HTTKDM4EKMT2ALMNA | |
| SCHEMBL11631591 | 0.78 | HTT (0.46) | ALDH1A1HTTKDM4ENPC1KMT2A | |
| SCHEMBL10087171 | 0.78 | HTT (0.46) | ALDH1A1HTTKDM4ENPC1KMT2A | |
| SCHEMBL14275210 | 0.78 | HTT (0.46) | ALDH1A1HTTKDM4ENPC1KMT2A | |
| SCHEMBL6168684 | 0.78 | HTT (0.50) | ALDH1A1HTTKDM4ENPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2017066742-A1 | BACE-2 INHIBITORY COMPOUNDS AND RELATED METHODS OF USE | JORTAN PHARMACEUTICALS INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-9458110-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-7713961-B2 | Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| EP-2025672-A1 | SEVEN-MEMBERED RING COMPOUND, PRODUCTION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Asubio Pharma Co., Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007020502-A2 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007017511-A2 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007014946-A1 | SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2003035060-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003006490-A1 | BRIDGED BICYCLIC SERINE PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | ALDH1A1 3223/4885HTT 4140/4885KDM4E 786/4885 |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | ALDH1A1 29/4885HTT 1100/4885KDM4E 1639/4885 |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | PSEN1, PSEN2, BACE1 | ALDH1A1 511/4885HTT 181/4885KDM4E 484/4885 |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | ALDH1A1 3325/4885HTT 3207/4885KDM4E 4151/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | ALDH1A1 4673/4885HTT 2378/4885KDM4E 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.